Multivariate Analyses of Inflammatory Cytokines in Eyes with Branch Retinal Vein Occlusion: Relationships to Bevacizumab Treatment
Multivariate Analyses of Inflammatory Cytokines in Eyes with Branch Retinal Vein Occlusion: Relationships to Bevacizumab Treatment
复制标题
DOI：
10.1167/iovs.10-6299
复制
发表时间：
2011-05-01
影响因子：
4.4
通讯作者：
Inoue, Yoshitsugu
中科院分区：
文献类型：
--
作者：
Kaneda, Shuzo;Miyazaki, Dai;Inoue, Yoshitsugu
目的.目的探讨视网膜分支静脉阻塞（branch retinal vein occlusion，BRVO）患者眼内炎性细胞因子表达的差异及其作为BRVO预后决定因素的作用。38只BRVO患眼的前瞻性队列研究。在玻璃体内注射贝伐珠单抗之前收集房水样品，并评估18种细胞因子、趋化因子和生长因子。作为对照，收集白内障手术前28只眼的房水。BRVO患者眼房水中IL-23、IL-8、IL-6、IL-15、IL-12和IL-17水平均显著高于对照眼。治疗前视力与IL-8、IL-10、IL-2、IL-1 β、IL-5、IL-6、IL-23、IL-4、MCP-1、IL-1 α、IL-12、IL-13、IFN-γ和IL-15的浓度显著相关。预处理非灌注面积（NPA）与IL-8、IL-2、MCP-1和IL-6的浓度显著相关。Logistic回归分析显示BRVO与IL-8、IL-23、IL-12、IL-15、IL-10、IL-1 β和IL-13浓度之间存在显著相关性。IL-8具有最高的比值比（OR），并且与NPA、中央视网膜厚度（CRT）和视力显著相关。贝伐珠单抗治疗1个月后显著改善了视力和CRT。贝伐珠单抗难治性（定义为治疗后1个月CRT恢复，
PURPOSE. To characterize the differential expression of intraocular inflammatory cytokines in eyes with branch retinal vein occlusion (BRVO) and to assess their roles as prognostic determinants of BRVO.METHODS. A prospective cohort study of 38 eyes with BRVO. Aqueous humor samples were collected just before the intravitreal injection of bevacizumab and were assessed for 18 cytokines, chemokines, and growth factors. For control, aqueous humor was collected from 28 eyes before cataract surgery.RESULTS. In the aqueous of eyes with BRVO, the IL-23, IL-8, IL-6, IL-15, IL-12, and IL-17 levels were significantly higher than that in control eyes. Pretreatment visual acuity was significantly correlated with the concentrations of IL-8, IL-10, IL-2, IL-1 beta, IL-5, IL-6, IL-23, IL-4, MCP-1, IL-1 alpha, IL-12, IL-13, IFN-gamma, and IL-15. The pretreatment nonperfused area (NPA) was significantly correlated with the concentrations of IL-8, IL-2, MCP-1, and IL-6. Logistic regression analyses revealed significant associations between the BRVO and the concentrations of IL-8, IL-23, IL-12, IL-15, IL-10, IL-1 beta, and IL-13. IL-8 had the highest odds ratio (OR) and was significantly associated with NPA, central retinal thickness (CRT), and visual acuity. Bevacizumab treatment significantly improved visual acuity and CRT after 1 month. Refractoriness to bevacizumab (defined as CRT recovery 1 month after treatment by